Vivos Therapeutics (VVOS) Equity Ratio (2019 - 2025)
Vivos Therapeutics (VVOS) has disclosed Equity Ratio for 7 consecutive years, with 0.1 as the latest value for Q3 2025.
- On a quarterly basis, Equity Ratio fell 80.23% to 0.1 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.1, a 80.23% decrease, with the full-year FY2024 number at 0.52, up 1258.65% from a year prior.
- Equity Ratio was 0.1 for Q3 2025 at Vivos Therapeutics, down from 0.18 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.79 in Q3 2021 to a low of 0.0 in Q3 2023.
- A 5-year average of 0.42 and a median of 0.41 in 2023 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: plummeted 99.17% in 2023, then skyrocketed 11101.71% in 2024.
- Vivos Therapeutics' Equity Ratio stood at 0.76 in 2021, then plummeted by 53.84% to 0.35 in 2022, then plummeted by 89.05% to 0.04 in 2023, then soared by 1258.65% to 0.52 in 2024, then plummeted by 81.03% to 0.1 in 2025.
- Per Business Quant, the three most recent readings for VVOS's Equity Ratio are 0.1 (Q3 2025), 0.18 (Q2 2025), and 0.39 (Q1 2025).